HealthDay News — The maker of RpiPen, Mylan, has stated that it is recalling select lots of EpiPen and EpiPen Jr due to a defect that might render it difficult to activate in an emergency.

Mylan said the recall was prompted by two reports — both occurring outside the United States — of the products’ failure to activate because of a potential defect in a component part.

“The incidence of the defect is extremely rare, and testing and analysis across the potentially impacted lots has not identified any units with a defect,” the company said in a news release. 


Continue Reading

“However, the recall is being expanded to include additional lots as a precautionary measure out of an abundance of caution.

The recall impacts the 0.3 mg and 0.15 mg strengths of EpiPen Auto-Injector. None of the recalled lots include the authorized generic for EpiPen Auto-Injector.”

Meridian Medical Technologies, a Pfizer company, is Mylan’s manufacturing partner for EpiPen Auto-Injector.

Reference

Update on Meridian’s Voluntary Worldwide Recall of EpiPen® Auto-Injector. Mylan. Updated April 3, 2017. Available at: http://www.mylan.com/en/epipenrecall. Accessed April 4, 2017.

Related Articles